Technical Analysis for PTCT - PTC Therapeutics, Inc.

Grade Last Price % Change Price Change
F 42.90 -2.78% -1.23
PTCT closed up 1.43 percent on Friday, June 2, 2023, on 78 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction -2.78%
Narrow Range Bar Range Contraction -2.78%
Doji - Bearish? Reversal -2.78%
Wide Bands Range Expansion -2.78%
Up 3 Days in a Row Strength -2.78%
Oversold Stochastic Weakness -2.78%
Slingshot Bearish Bearish Swing Setup -1.39%
Lower Bollinger Band Walk Weakness -1.39%
Wide Bands Range Expansion -1.39%
Oversold Stochastic Weakness -1.39%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 2 hours ago
Down 3% about 3 hours ago
Fell Below Previous Day's Low about 4 hours ago
Down 2 % about 4 hours ago
Down 1% about 4 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


PTC Therapeutics, Inc. Description

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and proprietary small-molecule drugs for patients living with serious and life-threatening conditions, including genetic and neuromuscular disorders, cancer, and infectious diseases. Its approach includes post-transcriptional control, RNA biology, and gene expression modulation by small-molecules. The company has strategic alliances with AstraZeneca; Celgene Corporation; Cystic Fibrosis Foundation; Genzyme Corporation; Gilead; Muscular Dystrophy Association; Merck & Co., Inc.; Parent Project Muscular Dystrophy; Pfizer Inc.; Roche; Spinal Muscular Atrophy Foundation; and Wellcome Trust. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Biology Infectious Diseases Neurological Disorders Gene Expression Dystrophy Cystic Fibrosis Muscular Dystrophy Neurodegenerative Disorders Transcription Spinal Muscular Atrophy Genzyme Neuromuscular Disorders

Is PTCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 59.75
52 Week Low 25.04
Average Volume 873,603
200-Day Moving Average 46.64
50-Day Moving Average 51.08
20-Day Moving Average 51.96
10-Day Moving Average 47.97
Average True Range 2.69
RSI (14) 35.06
ADX 33.06
+DI 17.40
-DI 37.17
Chandelier Exit (Long, 3 ATRs) 51.68
Chandelier Exit (Short, 3 ATRs) 49.03
Upper Bollinger Bands 64.96
Lower Bollinger Band 38.97
Percent B (%b) 0.2
BandWidth 50.02
MACD Line -2.66
MACD Signal Line -1.06
MACD Histogram -1.5922
Fundamentals Value
Market Cap 3.01 Billion
Num Shares 68.2 Million
EPS -4.10
Price-to-Earnings (P/E) Ratio -10.76
Price-to-Sales 11.48
Price-to-Book 8.55
PEG Ratio 0.81
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 46.13
Resistance 3 (R3) 46.00 45.20 45.80
Resistance 2 (R2) 45.20 44.69 45.27 45.68
Resistance 1 (R1) 44.66 44.37 44.93 44.79 45.57
Pivot Point 43.86 43.86 44.00 43.93 43.86
Support 1 (S1) 43.32 43.35 43.59 43.45 42.67
Support 2 (S2) 42.52 43.03 42.59 42.56
Support 3 (S3) 41.98 42.52 42.45
Support 4 (S4) 42.11